![]() | ![]() |
Formats:
|
||||||||||
Copyright © 2006 Bennasser and Jeang; licensee BioMed Central Ltd. HIV-1 Tat interaction with Dicer: requirement for RNA 1Molecular Virology Section, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-0460, USA Corresponding author.Yamina Bennasser: ybennasser/at/mail.nih.gov; Kuan-Teh Jeang: kj7e/at/nih.gov Received December 12, 2006; Accepted December 20, 2006. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC.Abstract Dicer is an RNase III which processes two classes of cellular small RNAs: the microRNAs (miRNA) and short interfering RNAs (siRNA). Previously, we observed that over-expressed HIV-1 Tat protein can suppress the processing of small RNAs inside cells. Here, we have investigated the requirements for Tat interaction with Dicer. We report that Tat-Dicer interaction depends on RNA, requires the helicase domain of Dicer, and is independent of Tat's transactivation domain. Findings The cell's RNA interference (RNAi) machinery is involved in either the inhibition of gene expression by sequence-specific cleavage of mRNAs or translational silencing of targeted RNAs [1-3]. One component of the RNAi machinery is Dicer, an ATP-dependent RNase III, which processes two classes of small RNAs: microRNA (miRNA) and short interfering RNA (siRNA) [4]. In the cytoplasm, Dicer recognizes a pre-miRNA, a short hairpin structure containing an imperfect stem, and generates small mature miRNA duplexes of 21 to 25 nucleotides. Pre-miRNAs originate from nuclear pri-miRNAs which are RNA polymerase II transcribed cellular transcripts that are processed by another RNase III protein, Drosha. Processed pre-miRNAs are shuttled from the nucleus into the cytoplasm by the exportin-5 protein. In the cytoplasm, a Dicer-miRNA complex recognizes a dsRNA binding protein called TRBP (for "TAR RNA binding protein"). TRBP connects Dicer-miRNA into the RNA induced silencing complex (RISC) through interaction with the argonaute 2 (Ago-2) protein [5,6]. Within RISC, one strand of the miRNA duplex is retained and serves as a guide RNA for base-complementary recognition of RNA-targets. It is currently thought that miRNA-RISC captures target transcripts through guide RNA – target RNA base complementarity; the target RNA is subsequently translationally silenced by sequestration into ribosome-free cytoplasmic compartments called processing bodies (P-bodies) [7,8]. Because miRNA-RISC mediated translational inhibition of target mRNA does not require perfect miRNA-mRNA complementarity, one miRNA is in principle capable of silencing the translation of more than one hundred cellular transcripts [9]. In this respect, eucaryotic miRNAs are reasoned to be potentially capable of regulating the protein expression of more than 30 % of cellular genes [10]. In addition to its role in miRNA processing, Dicer also recognizes dsRNAs which originate from viruses, transgenes or transposons and cleaves them into small duplexes of 18 to 21 nucleotides called siRNA [11]. Like miRNAs, one strand of siRNAs is incorporated into RISC to be used as a guide sequence [12]. siRNA-guided RISC requires perfect complementarity with target mRNAs to promote not translational silencing but ribonuclease-mediated degradation of targeted transcripts. It has been proposed that mammalian cells may use RNAi as a defense against infection by viruses [13-15]. However, because most viral infections seem to progress efficiently in cells, one surmises that many viruses have developed stratagems to evade or suppress the cell's RNAi machinery [13,16,17]. Several extant observations are consistent with an RNAi thrust-and-parry interplay between the cell and the virus. For example, HIV-1 infection appears to down regulate the cell's miRNA processing [18], perhaps by encoding a partially effective suppressors of RNAi processing [16,19]. HIV-1 can also mutate its coding sequence to evade base-pair complementarity driven RNAi [20]. Additionally, HIV-1 can encode small si-/mi- RNA-like decoys, such as TAR RNA, which can squelch TRBP making this critical factor unavailable for authentic si-/mi- RNA processing [21,22]. We previously suggested that the HIV-1 Tat protein can act to suppress si-/mi- RNA processing [19]. In our experiments, over-expression of Tat in cells reduced the efficiency of shRNA-mediated RNAi. We also noted that Tat can inhibit Dicer activity in vitro. This activity of Tat was separate from its trans-activation function since a trans-activation inactive TatK41A mutant still retained suppression of RNA silencing (SRS) activity [19]. Here, we characterized the requirements for over-expressed Tat to interact with Dicer. Tat interaction with Dicer requires RNA We assayed Tat interaction with Dicer by transfecting 293T cells with myc-tagged Dicer (pDicer-myc) in the absence or presence of flag-tagged Tat (pTat-flag) (Figure (Figure1).1
We expressed Tat, TatK51A and TatK41A comparably (Figure (Figure1A,1A Because Tat and Dicer are both RNA-binding proteins, we wondered next if their interaction required RNA. To address this question, lysates from cells transfected with myc-Dicer and Tat proteins were divided into two groups prior to immunoprecipitation. One group was treated with RNase A while the other group was not (Figure (Figure1B).1B Dicer's helicase domain is required for interaction with Tat We next characterized the region in Dicer needed for Tat interaction. Co-immunoprecipation assays were performed using flag-tagged Dicer mutants deleted progressively from the N-terminus to encompass the DEAD domain (ΔDEAD), the Helicase domain (ΔHelicase), the Domain of Unknown Function 283 (ΔDUF), and the PAZ domain (ΔPAZ) (Figure 2A, B
We performed two controls for the above experiment. First, we checked that Tat was equally expressed in the lysates of all the transfections (Figure (Figure2A,2A We noted with interest that while the interaction of Tat and Dicer is RNA dependent (Figure (Figure1),1 Tat's trans-activation domain is dispensable for Dicer-association We next characterized the region in Tat required to association with Dicer. We performed GST-pull down assays since we had access to a large number of GST-Tat deletion mutants and because our immunoprecipitation of Tat proteins was uneven with differently deleted Tat mutants. Using GST-Tat mutants that included Tat's transactivation domain (Tat 1–45), or Tat's basic region (Tat 1–60), or GST-Tat mutants that were deleted in their transactivation domain but retained their middle regions (Tat 20–72, Tat 30–72; Figure Figure3B),3B
Here we have characterized some of the requirements for Tat-Dicer physical association. We found that Tat-Dicer interaction requires RNA, although simple protein-protein bridging by RNA does not seem to be a sufficient explanation. Dicer-Tat interaction also requires Dicer's helicase domain and a portion of Tat's 30–72 amino acids. Whether the latter requirements imply direct protein-protein contact remains to be established. List of abbreviations Ago-2 argonaute 2 miRNA microRNA RNAi RNA interference siRNA short interfering RNA TRBP TAR RNA binding protein Competing interests The author(s) declare that they have no competing interests. Authors' contributions YB carried out the experiments. YB and KTJ conceived of the study and wrote the manuscript. Acknowledgements We would like to thank Dr. Patrick Provost and Dr. Narry V. Kim for providing the wt Dicer and mutant Dicer constructs, respectively. Work in KTJ's laboratory is supported in part by the IATAP program from the Office of the Director, NIH. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||
Nature. 2002 Jul 11; 418(6894):244-51.
[Nature. 2002]Nat Rev Genet. 2002 Oct; 3(10):737-47.
[Nat Rev Genet. 2002]Genes Dev. 2001 Oct 15; 15(20):2654-9.
[Genes Dev. 2001]Nature. 2005 Aug 4; 436(7051):740-4.
[Nature. 2005]EMBO Rep. 2005 Oct; 6(10):961-7.
[EMBO Rep. 2005]Cell. 2005 Nov 18; 123(4):607-20.
[Cell. 2005]Nat Cell Biol. 2005 Jul; 7(7):719-23.
[Nat Cell Biol. 2005]Nature. 2005 Feb 17; 433(7027):769-73.
[Nature. 2005]Nat Rev Genet. 2005 Mar; 6(3):206-20.
[Nat Rev Genet. 2005]Retrovirology. 2006 Jan 12; 3():3.
[Retrovirology. 2006]Retrovirology. 2005 Oct 27; 2():65.
[Retrovirology. 2005]Retrovirology. 2005 Dec 28; 2():81.
[Retrovirology. 2005]Immunity. 2005 May; 22(5):607-19.
[Immunity. 2005]Immunity. 2005 May; 22(5):607-19.
[Immunity. 2005]EMBO J. 2006 Feb 8; 25(3):522-32.
[EMBO J. 2006]EMBO J. 2006 Feb 8; 25(3):522-32.
[EMBO J. 2006]EMBO Rep. 2004 Feb; 5(2):189-94.
[EMBO Rep. 2004]EMBO J. 2006 Feb 8; 25(3):522-32.
[EMBO J. 2006]Retrovirology. 2004 Dec 15; 1():43.
[Retrovirology. 2004]